KevinJosephCullenMD

Oncology • Baltimore, MD

Head & Neck Cancer, Hematologic Oncology

Professor, Medicine, University of Maryland School of Medicine

Join to view full profile

Dr. Cullen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cullen's full profile

Already have an account?

Office
22 S Greene St
Baltimore, MD 21201
Phone+1 410-328-6841

Fax+1 410-328-2578

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1986 - 1987
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1983 - 1986
Harvard Medical SchoolClass of 1983

Certifications & Licensure

MD State Medical License 1987 - 2026
DC State Medical License 1988 - 2004
VA State Medical License 2001 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Super Doctor SuperDoctors.com

Clinical Trials

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2

Publications & Presentations

PubMed

1147 citations
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Marshall R. Posner, Diane Hershock, Cesar R. Blajman, Elizabeth Mickiewicz, Eric Winquist
The New England Journal of Medicine. 2007-10-25
224 citations
Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients
Kathleen Settle, Marshall R. Posner, Lisa M. Schumaker, Ming Tan, Mohan Suntharalingam
Cancer Prevention Research. 2009-09-01
50 citations
A Phase I Dose Escalation Trial of MAGE-A3 and HPV16 Specific Peptide Immunomodulatory Vaccines in Patients with Recurrent / Metastatic (RM) Squamous Cell Carcinoma of...
Dan P. Zandberg, Sandra Rollins, Olga Goloubeva, Robert E. Morales, Ming Tan
Cancer Immunology, Immunotherapy. 2015-03-01

Press Mentions

Dr. Kevin Cullen to Retire as Director of the University of Maryland Greenebaum Comprehensive Cancer Center in 2023January 17th, 2023
Maryland Half Marathon and 5k Supports Cutting-Edge Research at University of Maryland Greenebaum Comprehensive Cancer CenterMay 26th, 2022
Governor Hogan Announces Maryland Cancer Moonshot InitiativeMarch 31st, 2022
Join now to see all

Grant Support

Translational LaboratoryNational Cancer Institute2011
Structural BiologyNational Cancer Institute2011
Radiation Linear Shared ServiceNational Cancer Institute2011
Protocol Specific ResearchNational Cancer Institute2011
Protocol Review And Monitoring SystemNational Cancer Institute2011
ProteomicsNational Cancer Institute2011
Program LeadersNational Cancer Institute2011
Planning And EvaluationNational Cancer Institute2011
Pathology And BiorepositoryNational Cancer Institute2011
Genomics - Shared ServicesNational Cancer Institute2011
Flow CytometryNational Cancer Institute2011
Data And Safety MonitoringNational Cancer Institute2011
Clinical Research Shared ServicesNational Cancer Institute2011
Biostatistics Shared ServiceNational Cancer Institute2011
Animals Shared ServiceNational Cancer Institute2011
AdministrationNational Cancer Institute2011
University Of Maryland Greenebaum Cancer Center Support GrantNational Cancer Institute2008–2011
Senior LeadershipNational Cancer Institute2008–2011
Developmental FundsNational Cancer Institute2008–2011
Program And Planning And EvaluationNational Cancer Institute2008–2010
Prognostic Markers In Trials For Head And Neck CancerNational Cancer Institute2004–2005
AP4 Planning For Targeted Drugs In Orphan CancersNational Cancer Institute2004
Greenbaum Cancer Center, University Of MarylandNational Cancer Institute2001–2004
Prognostic Markers In Trials For Head And Neck CancerNational Cancer Institute2003
Midcareer Investigator AwardNational Cancer Institute2003
Midcareer Investigator AwardNational Cancer Institute1999–2003
Cancer Center Support GrantNational Cancer Institute2001–2002
Clinical Oncology Research Career Development ProgramNational Cancer Institute2000–2002
Insulin LIKE Growth Factor II In Breast CancerNational Cancer Institute1997–1999
Predicting Chemotherapy Response In Head And Neck CancerNational Cancer Institute1997–1998
Stromal/Epithelial Interactions In Breast CancerNational Cancer Institute1995
Insulin-Like Growth Factor II In Breast CancerNational Cancer Institute1993–1995
Stromal-Epithelial Interactions In Breast CancerNational Cancer Institute1991–1995